Sunrise to expand hyperopia laser trials:
This article was originally published in Clinica
Executive Summary
Sunrise Technologies is to expand US trials of its laser treatment for farsightedness after receiving permission from the FDA to test the device in patients with higher levels of hyperopia. The office-based Laser Thermal Keratoplasty system will be assessed in patients with hyperopia from +2.75 to +4.0 dioptres said the Fremont, California-based company. Sunrise has already submitted the device to the agency for approval in patients with hyperopia of between +0.75 and +2.50 dioptres. An FDA-panel is expected to review the premarket approval application in July.